KalVista Pharmaceuticals, Inc.

Healthcare · Biotechnology · United States

Last price 27 USD (At close: Jun 10, 2026) · Market cap 1.44B

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

KalVista Pharmaceuticals, Inc., a biopharmaceutical company, develops oral therapies for individuals for rare diseases with unmet needs. Its lead product candidate is EKTERLY, a fast-acting potent inhibitor of plasma kallikrein for the treatment of acute attacks of hereditary angioedema (HAE). The company is also developing is developing an orally disintegrating tablet formulation; KONFIDENT-KID for pediatric use with HAE; KONFIDENT; and KONFIDENT-S to evaluate sebetralstat and ODT formulation in adolescent and adult patients. KalVista Pharmace...